This asthma drug can boost recovery in COVID-19
In a new study from the University of Oxford, researchers found that early treatment with an asthma drug budesonide shortens recovery time in COVID-19 patients aged over 50 who are treated at home.
They found clear evidence of an effective COVID-19 treatment for use in primary care that can significantly shorten recovery time.
Inhaled budesonide is a safe, relatively inexpensive and readily available corticosteroid commonly used around the world in inhalers to treat asthma and chronic obstructive pulmonary disease.
In the study, a total of 961 patients were assigned to receive inhaled budesonide at home. These were compared with 1819 patients assigned to the usual standard of NHS care alone.
Of these, 751 people in the budesonide group, and 1028 in the usual care group were SARS-CoV-2 positive and included in the primary interim analysis.
The results showed the estimated median time to self-reported recovery for inhaled budesonide was:
3.01 days shorter compared to usual care; with a high probability (0.999) of being superior to the usual standard of care;
32% of those taking inhaled budesonide, compared to 22% in the usual care group, recovered within the first 14 days; and they have subsequently remained well until 28 days.
Participants in the budesonide group also reported greater well-being after two weeks.
The team says for the first time they have high-quality evidence of an effective treatment that can be rolled out across the community for people who are at most risk of developing more severe illness from COVID-19.
Unlike other proven treatments, budesonide is effective as a treatment at home and during the early stages of the illness. This is a significant milestone for this pandemic.
If you care about COVID-19, please read studies about these 3 things could strongly predict COVID-19 death and findings of this hormone may curb COVID-19 inflammation, prevent ‘cytokine storm’.
For more information about COVID-19 prevention and treatment, please see recent studies about this gut inflammation may be an early sign of COVID-19 and results showing that this anti-viral treatment can have double effects on COVID-19.
The study is posted on the medRxiv. One author of the study is Professor Richard Hobbs.
Copyright © 2021 Knowridge Science Report. All rights reserved.